Saturday, October 30, 2010 Hall A - Multiple Sclerosis |
Session 14: Etiology and Pathogenesis of MS |
DOES CHRONIC VENOUS INSUFFICIENCY PLAY A ROLE IN MS PATHOGENESIS? YES P. Zamboni |
 |
DOES CHRONIC VENOUS INSUFFICIENCY PLAY A ROLE IN MS PATHOGENESIS? NO O. Stüve |
 |
|
 |
ARE INFECTIONS KEY ENVIRONMENTAL FACTORS IN MS? NO A. Chaudhuri |
 |
|
|
Session 16: New Players in MS |
|
SHOULD ALL MS PATIENTS BE TREATED WITH STATINS? YES O. Stüve |
 |
SHOULD ALL MS PATIENTS BE TREATED WITH STATINS? NO R. Milo |
 |
FUMARATE J. Losy |
 |
BONE MARROW TRANSPLANTATION D. Karussis |
 |
TERIFLUNOMIDE M. Freedman |
 |
LAQUINIMOD P. Vermersch |
 |
CLADRIBINE P. Rieckmann |
 |
EMERGING TREATMENTS FOR PSEUDOBULBAR AFFECT D. Wynn |
 |
|
|
Saturday, October 30, 2010 Hall B - Headache / Pain |
|
Session 19 Headache: What causes post traumatic headache - Will CRGP antagonists be effective? |
|
WILL THE FIRST MARKETED CGRP ANTAGONIST BE AN IMPORTANT ADDITION TO THE MIGRAINE TREATMENT ARMAMENTARIUM? YES A. Rapoport |
 |
WILL THE FIRST MARKETED CGRP ANTAGONIST BE AN IMPORTANT ADDITION TO THE MIGRAINE TREATMENT ARMAMENTARIUM? NO M. Levin |
 |
COMMENTARY N. Mathew |
 |
|
|
Session 28: Biomarkers in Diagnositcs of Neurological Disorders |
|
THE PLACE OF SURROGATE ENDPOINTS IN THE DEVELOPMENT OF NEW NEUROLOGICAL MEDICINES P. Feldschreiber |
 |